AdAlta Ltd (ASX:1AD)'s Tim Oldham discusses the company's latest patent protection milestone, giving it patent coverage in eight of the world's largest pharmaceutical markets. Oldham says the European patent means AdAlta's lead program, AD-214, now has patent protection until 2036 in the eight largest pharmaceutical markets in the world: the US, Japan, China, Germany, France, Italy, Spain and the UK.
AdAlta secures European patent for AD-214 and progresses partnering at BIO International Convention
